|
For immediate release
|
29 July
2024
|
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Result of AGM
Alliance Pharma plc
(AIM: APH), the international healthcare group,
announces that, at its Annual General Meeting held earlier today,
all the resolutions except resolutions 16 and 17, as set out in the
Notice of Meeting, were duly passed on a poll.
The number of the Group's shares in
issue as at the date of the meeting was 540,565,539
ordinary shares of 1p each*.
The votes were as
follows:
|
RESOLUTION
|
VOTES
FOR
|
%
|
VOTES
AGAINST
|
%
|
VOTES
WITHHELD
|
|
1
|
Report and Accounts
|
190,733,158
|
99.99
|
14,451
|
0.01
|
12,870
|
|
2
|
Approve Remuneration
Report
|
118,424,151
|
62.09
|
72,319,389
|
37.91
|
16,939
|
|
3
|
Elect C. Pane
|
167,821,883
|
99.34
|
1,108,987
|
0.66
|
21,829,609
|
|
4
|
Elect R. McKenzie
|
190,719,135
|
99.98
|
28,979
|
0.02
|
12,365
|
|
5
|
Elect EL. Sjostedt
|
190,672,019
|
99.96
|
76,095
|
0.040
|
12,365
|
|
6
|
Elect N. Sedgwick
|
190,708,640
|
99.98
|
38,979
|
0.020
|
12,860
|
|
7
|
Re-elect A. Franklin
|
190,546,663
|
99.89
|
201,451
|
0.11
|
12,365
|
|
8
|
Re-elect J. Heper (Withdrawn)
|
-
|
-
|
-
|
-
|
-
|
|
9
|
Re-elect R. Jones
|
119,208,411
|
62.55
|
71,381,969
|
37.45
|
170,099
|
|
10
|
Re-elect K. Neirynck
|
190,554,413
|
99.98
|
36,462
|
0.02
|
169,604
|
|
11
|
Re-elect M. Sutherland
|
119,879,952
|
62.90
|
70,710,923
|
37.10
|
169,604
|
|
12
|
Appointment of Auditor
|
190,656,799
|
99.95
|
90,085
|
0.05
|
13,595
|
|
13
|
Remuneration of Auditor
|
190,715,105
|
99.98
|
32,274
|
0.02
|
13,100
|
|
14
|
Allot shares - general
|
119,812,913
|
62.81
|
70,933,841
|
37.19
|
13,725
|
|
15
|
Allot shares - additional
|
120,008,767
|
62.92
|
70,735,963
|
37.08
|
15,749
|
|
16
|
Disapply pre-emption rights -
general
|
119,970,667
|
62.90
|
70,776,712
|
37.10
|
13,100
|
|
17
|
Disapply pre-emption rights -
additional
|
119,912,206
|
62.86
|
70,835,173
|
37.14
|
13,100
|
The Board notes the votes against
Resolutions 2, 9, 11, 14, 15, 16 and 17 and
will consult with shareholders to understand their views and
publish the results of that consultation in due course.
Chris Chrysanthou
Group General Counsel & Company Secretary
29 July 2024
*Each share carries one vote and a 'vote withheld' is not a
vote in law and has not been counted in the calculation of the
proportion of the votes for and against the resolution. Any proxy
appointments which gave discretion to the Chairman have been
included in the 'votes for' total.
For further information:
|
Alliance Pharma plc
|
+ 44
(0)1249 466966
|
|
Cora McCallum, Head of Investor
Relations & Corporate Communications
|
+ 44
(0)1249 705168
|
|
ir@allianceph.com
|
|
|
|
|
|
Buchanan
|
+ 44 (0)20
7466 5000
|
|
Mark Court / Sophie Wills
|
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser
and Joint Broker)
|
+ 44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
|
|
|
Investec Bank plc (Joint
Broker)
|
+ 44 (0)20
7597 5970
|
|
Patrick Robb / Ben Lawrence / Maria
Gomez de Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 290 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com